Within two to four weeks we find potential targets/biomarker candidates or do a detailed target/biomarker assessment. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll contact you to discuss next steps.

Use our platform to find novel target/biomarker candidates or do detailed target/biomarker assessment yourselves. This will save you months of painstaking on-line desk research. Enter your contact details and we’ll set up a demo to show you!

Please contact me to discuss:

Subscription to Euretos AI Platform
Euretos consulting service
Direct access to Euretos API

Do you have a question on gene-disease associations that are not covered on this page? Or would you like to know more about the Euretos AI Platform? Please fill in your contact details and we will reach out to you!




Literature monitoring by Euretos detects over 550 ‘first ever’ gene-cancer mentions in Pubmed each month



Friday 14 December 2018

In a recent study published in Cellular SIgnalling, researchers identified MAP2K6 (also known as MKK6) as a novel potential target for Esophageal adenocarcinoma (EAC), an aggressive form of cancer with a 5-year survival rate of less than 15%. As part of a drug repurposing study, it was found that the drug Ouabain inhibits MAP2K6, leading to reduced levels of the transcription factor SOX9 which in turn decreased EAC cell growth and proliferation.

This was the first time ever that MAP2K6 was mentioned with EAC in an abstract of a publication; making it a significant first co-mention. Within the Euretos AI Platform, such ‘abstract level’ gene-disease novelties are monitored continuously as these have a higher likelihood of being significant. In cancer literature alone, over 550 novel gene-disease mentions are published each month! Given the potential value of these publications, Euretos provides a service to track such novelties, taking into account the many synonyms that are used for genes as well as diseases. MAP2K6, for instance, has over 20 different synonyms that the Euretos platform automatically recognises:

Figure 1: Synonyms and database identifiers for MAP2K6 that are known by the Euretos AI Platform (source: Euretos AI Platform)

However, as these abstract level gene-disease mentions are novel, the availability of further analysis is often quite limited. The same is true in the case of MAP2K6 where much is still unknown regarding the specific interactions that MAP2K6 has in the context of EAC as well as in other types of adenocarcinomas.

Figure 2: Publications mentioning both MAP2K6 and adenocarcinoma in the abstract or as declared by the authors. Only 13 publications are available. Euretos provides a ‘featured’ result which enables a detailed analysis of MAP2K6 involvement in adenocarcinoma. (source: Euretos AI Platform)

Although there is very limited direct literature on the role of MAP2K6 in EAC and adenocarcinomas in general, further analysis is possible by including the disease-specific protein network associated with MAP2K6 in the analysis. Using the Euretos Gene-Disease workflow the MAP2K6 protein network is highly involved in adenocarcinomas:


Figure 3: Gene-Disease Analysis workflow showing the top 15 genes that are associated with MAP2K6 and esophageal neoplasms (source: Euretos AI Platform)

Using the MAP2K6 protein network as the basis for further analysis, the Gene-Disease workflow evaluates key aspects including involvement in esophageal neoplasm related differential expression, gene mutations, animal models, metabolic interactions and key physiological processes such as pathways, phenotypes, molecular dysfunctions and cell & tissue functions.

In terms of adenocarcinoma dysregulation, for instance, MAP2K6 is co-dysregulated with 14 other genes:

 

Figure 4: Dysregulation analysis of MAP2K6 in adenocarcinoma (source: Euretos AI Platform)

In terms of cellular and molecular dysfunctions, for instance, MAP2K6 plays a role in dna damage, aneuploidy and, especially interesting in the EAC context, intestinal metaplasia. Many of these interactions are not directly associated with MAP2K6, but with interacting proteins, associations which are normally hard to find:

 

Figure 5: Cellular and molecular dysfunction analysis of MAP2K6 and it’s gene interactome revealing key associations with esophageal neoplasms (source: Euretos AI Platform)

In Barrett Esophagus, a precursor for EAC, MAP2K6 is involved in re-epithelialization, one of the major processes in the formation of esophageal adenocarcinoma.

 

Figure 6: Organ and tissue function analysis of MAP2K6 and it’s gene interactome revealing key associations with Barrett Esophagus, the precursor to EAC (source: Euretos AI Platform)

In conclusion, although very limited direct literature exists of the involvement of MAP2K6 in esophageal neoplasms and adenocarcinoma, the Gene-Disease Analysis workflow reveals many relevant associations. Through its protein network, MAP2K6 is involved in various key mechanisms such as re-epithelialization, intestinal metaplasia, tumor metastasis and survival.

The full analysis is available on request via the contact form on the Euretos website or at information@euretos.com

Read more news articles: Euretos News

About this series - The purpose of the Euretos Research Note series is to provide a data analytics perspective on recent life sciences publications. The series focuses on two types of questions: (1) Did the available data already point in the direction of a discovery? (2) What further research angles does the available data and publications suggest?